Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS9051b in Advanced ACC and mCRPC
NCT07189403Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of DS9051b in adrenocortical carcinoma (ACC) and castration-resistant prostate cancer (CRPC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting Toxicities at 50 months and Treatment-emergent Adverse Events at 50 months. Started Nov 2025; status: recruiting.
02
Drugs
DS9051b
03
Conditions
adrenocortical carcinoma (ACC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07189403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189403.